Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
Asemissen AM, Scheibenbogen C, Letsch A, Hellstrand K, Thorén F, Gehlsen K, Schmittel A, Thiel E, Keilholz U. Asemissen AM, et al. Among authors: gehlsen k. Clin Cancer Res. 2005 Jan 1;11(1):290-7. Clin Cancer Res. 2005. PMID: 15671558 Clinical Trial.
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi P. Agarwala SS, et al. Among authors: gehlsen kr. J Clin Oncol. 2002 Jan 1;20(1):125-33. doi: 10.1200/JCO.2002.20.1.125. J Clin Oncol. 2002. PMID: 11773161 Clinical Trial.
Histamine: a novel approach to cancer immunotherapy.
Hellstrand K, Brune M, Naredi P, Mellqvist UH, Hansson M, Gehlsen KR, Hermodsson S. Hellstrand K, et al. Among authors: gehlsen kr. Cancer Invest. 2000;18(4):347-55. doi: 10.3109/07357900009012178. Cancer Invest. 2000. PMID: 10808371 Review.
Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
Middleton M, Hauschild A, Thomson D, Anderson R, Burdette-Radoux S, Gehlsen K, Hellstrand K, Naredi P. Middleton M, et al. Among authors: gehlsen k. Ann Oncol. 2007 Oct;18(10):1691-7. doi: 10.1093/annonc/mdm331. Epub 2007 Aug 20. Ann Oncol. 2007. PMID: 17709802 Free article. Clinical Trial.
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, Wallhult E, Hellstrand K. Brune M, et al. Among authors: gehlsen k. Blood. 2006 Jul 1;108(1):88-96. doi: 10.1182/blood-2005-10-4073. Epub 2006 Mar 23. Blood. 2006. PMID: 16556892 Free article. Clinical Trial.
A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C.
Lurie Y, Nevens F, Aprosina ZG, Fedorova TA, Kalinin AV, Klimova EA, Ilan Y, Maevskaya MV, Warnes TW, Yuschuk ND, Hellstrand K, Gehlsen KR. Lurie Y, et al. Among authors: gehlsen kr. J Viral Hepat. 2002 Sep;9(5):346-53. doi: 10.1046/j.1365-2893.2002.00378.x. J Viral Hepat. 2002. PMID: 12225329 Clinical Trial.
46 results